1. Introduction
===============

Prostate cancer is the most common malignant tumor and the second most common cause of cancer death in the male population \[[@b1-ijms-13-06138]\]. The current treatment for prostate cancer is a combination of surgery, radiation, and chemotherapy \[[@b2-ijms-13-06138]\]. As prostate cancer development and disease progression is hormone dependent, blockade of androgen action is the foundation of most popular therapies \[[@b3-ijms-13-06138]\]. Castration-resistant prostate cancer (CRPC) is an advanced status of prostate cancer associated with high death rates \[[@b4-ijms-13-06138]\]. Treatment options for CRPC are an unmet need, with current anti-androgens having been shown only to prolong survival \[[@b5-ijms-13-06138]\]. The androgen receptor (AR) is postulated to play a key mediator of prostate cancer \[[@b6-ijms-13-06138]\]. Over the past 2 decades, several important mechanisms of mutation in AR have been elucidated. Laboratory observations have offered clues that AR mutations have turned the growth-inhibitory effect of the current clinically used anti-androgens into a growth-promoting effect at the castration-resistant form \[[@b5-ijms-13-06138],[@b6-ijms-13-06138]\]. This has led to an attractive strategy targeting mutant AR which offer promising potential in future treatment of CRPC.

In recent years, a number of androgen receptor antagonists have appeared, among them, Li Lin *et al*. synthesized a series of curcumin derivatives as potent selective AR antagonists. Some compounds showed significant cytotoxicity against human prostate cancer cell lines, androgen-dependent LNCaP. Anti-androgenic activity was also evaluated in LNCaP cells transfected with wild-type AR \[[@b2-ijms-13-06138]\]. In addition, the X-ray crystal structures of AR have been determined \[[@b7-ijms-13-06138]\] which provide useful information about the interaction with the residues near the binding site.

The three dimensional quantitative structure activity relationships (3D-QSAR) may be useful in drug discovery and design \[[@b8-ijms-13-06138]\]. As the most popular QSAR methods, Comparative Molecular Field Analysis (CoMFA) \[[@b9-ijms-13-06138]\] and Comparative Similarity Indices Analysis (CoMSIA) \[[@b10-ijms-13-06138]\] studies incorporate 3D information for the ligands by searching for sites on molecules capable of being modified into better specific ligands. As a useful methodology for studying the interaction mechanism, receptor based molecular docking analysis can offer vivid interaction picture between a ligand and an acceptor \[[@b11-ijms-13-06138]\]. Combined 3D-QSAR and docking study could offer more information to understand the structural features of bonding site of protein and the detail of protein--ligand interactions for purposive directing the design of new potential molecules \[[@b12-ijms-13-06138]\].

In this work, QSAR and docking studies of androgen receptor antagonists with anticancer activity against human prostate cancer cell line LNCaP were carried out. An optimal 3D QSAR model for these compounds was established, and the model can be used to predict quantitatively the properties of entry antagonists not in the data set. We expect that the results can offer some reference to guide the design of novel potent AR antagonists.

2. Material and Methods
=======================

2.1. Data Sets
--------------

All curcumin derivatives and their biological activities (IC50 values) were taken from the literature \[[@b2-ijms-13-06138]\]. In order to examine the predictive ability and robustness of the QSAR models, the test set of 7 molecules were selected randomly in such a way that the structural diversity and wide range of activity in the data set were included, and the remaining 33 compounds are treated as a training set and used to derive the 3D-QSAR models.

The structures of the compounds and their biological data are given in [Table 1](#t1-ijms-13-06138){ref-type="table"}. The cytotoxicity bioassay was performed according to the procedures described in Lin *et al*. \[[@b2-ijms-13-06138]\]. IC50 values are mean concentrations that inhibit growth by 50% and variation between replicates was less than 5%. The IC50 values in units of μM were transformed in pIC50 (-log IC50) in order to give numerically larger data values.

2.2. Molecular Modeling and Alignment
-------------------------------------

All molecular modeling and 3D-QSAR calculations were done using SYBYL X 1.3 (Tripos Associates Inc., St. Louis, Missouri, USA, 2011). Molecular building was done with a molecule sketch program on the same software. The molecular geometry of each compound was first minimized using a standard Tripos molecular mechanics force field with 0.01 kcal/(mol Å) energy gradient convergence criterion. Partial atomic charges were calculated by the Gasteiger-Hückel method and energy minimizations were performed using the Powell method 1000 iterations \[[@b13-ijms-13-06138]\].

The accuracy of the prediction of QSAR model and reliability of the contour maps are directly dependent on the structural alignment rule \[[@b14-ijms-13-06138]\]. In order to obtain the best possible 3D-QSAR statistical model, two different alignment rules were adopted. During the process, the lowest energy conformation of compound 29 was used as the template for the alignment, because it is one of the most active compounds in [Table 1](#t1-ijms-13-06138){ref-type="table"}. [Figure 1a](#f1-ijms-13-06138){ref-type="fig"} describes the common substructure for the alignment which is marked in bold. However, due to with no such substructure of [Figure 1a](#f1-ijms-13-06138){ref-type="fig"} in the structures, compounds 1--10, 28 and 31 were aligned based on another common substructure depicted in bold as shown in [Figure 1b,c](#f1-ijms-13-06138){ref-type="fig"} shows the resulting ligand-based alignment model.

2.3. CoMFA and CoMSIA Field Calculation
---------------------------------------

The standard CoMFA procedure as implemented by SYBYL X 1.3 was performed. For each aligned sets of molecules were positioned inside a 3D cubic lattice with a grid spacing of 2.0 Å (default distance) in all Cartesian directions was generated to enclose the molecule aggregate. A sp^3^ carbon atom with a charge of +1.0 and a van der Waals radius of 1.52 Å was used as a probe; this atom was placed at every lattice point to calculate various steric and electrostatic fields by the CoMFA standard method with default cut-off energy of 30.0 kcal/mol \[[@b15-ijms-13-06138]\]. In order to reduce noise and improve efficiency, column filtering was set to 1.0 kcal/mol. The fields generated were scaled by CoMFA standard in SYBYL automatically.

The CoMFA region focusing is the application of weights to the lattice points in a CoMFA region to enhance or attenuate the contribution of those points to subsequent analyses. When the weights are StDev\*Coefficient values, the process is exactly equivalent to image enhancement of the derived CoMFA maps for getting the better models \[[@b16-ijms-13-06138]\].

The CoMSIA method, discovered by Klebe \[[@b10-ijms-13-06138]\], has advantages over CoMFA technique such as greater robustness regarding both region shifts and small shifts within the alignments \[[@b16-ijms-13-06138]\]. With the standard parameters and no arbitrary cutoff limits, five fields associated, namely, steric, electrostatic, hydrophobic, hydrogen bond donor and hydrogen bond acceptor, were calculated using the same lattice box created for CoMFA. The default value of 0.3 was used as the attenuation factor.

2.4. Partial Least Square Analysis
----------------------------------

The partial least squares (PLS) methodology was used to derive a linear relationship for the 3D-QSAR, and cross-validation was performed using the leave-one-out(LOO) method \[[@b17-ijms-13-06138]\] to choose the optimum number of components (ONC) and assess the statistical significance of each model. In PLS, the independent variables were the CoMFA and CoMSIA descriptors, and pIC~50~ values were used as dependent variables \[[@b16-ijms-13-06138]\]. The ONC was the number of components that led to the highest cross-validated correlated correlation coefficient *q*^2^ (or *r*^2^ ~cv~). Before the PLS analysis, the CoMFA and CoMSIA columns were filtered by using column filtering. Non-cross-validation was performed to calculate conventional *r*^2^ ~ncv~ using the same number of components. To further assess the robustness and statistical confidence of the derived models, bootstrapping analysis for 100 runs was performed \[[@b9-ijms-13-06138],[@b18-ijms-13-06138]\].

2.5. Molecular Docking
----------------------

To determine the probable binding conformations and offer more insight into the understanding of the interactions of androgen receptor antagonists, molecular docking analysis was carried out using the Surflex Dock in SYBYL. The crystal structure of AR was retrieved from RCSB Protein Data Bank (PDB entry code: 1T65) \[[@b7-ijms-13-06138]\]. The protein structures were utilized in subsequent docking experiments without energy minimization. All ligands and water molecules have been removed at first, the polar hydrogen atoms and AMBER7FF99 charges were added. Protomol, a computational representation of the intended binding site, is used to guide molecular docking \[[@b19-ijms-13-06138]\]. Jinming Z. *et al*. predicted binding mode of AR antagonists in the antagonistic model of wild type AR ligand-binding domain (WT AR-LBD). E709, Q738, W741, M742, L880, L881, and V889 were key residues of the active site to form hydrogen bonds or a hydrophobic pocket \[[@b6-ijms-13-06138]\]. Therefore, the active sites were considered to be the potential receptor's binding sites. In view of this, residues mode was adopted to generate the protomol by specifying residues in the receptor near Helix 12 in this study. The protomol bloat value was set as 1 and the protomol threshold value as 0.5 when a reasonable binding pocket was obtained. Other parameters are established by default in software.

3. Results and Discussion
=========================

3.1. CoMFA and CoMFA Region Focusing
------------------------------------

The results of CoMFA studies are summarized in [Table 2](#t2-ijms-13-06138){ref-type="table"}. The optimal number of components was determined by selecting highest *q*^2^ value. PLS analysis showed a high *q*^2^ value of 0.564 with 6 components for CoMFA. The non-cross-validated PLS analysis results in a conventional *r*^2^ ~ncv~ of 0.986; F is 304.611, and a standard error of estimation (SEE) of 0.068. When these fields were focused, the *q*^2^ improved and produced highest *q*^2^ of 0.658 with 6 components, *F* = 352.278, *r*^2^ ~ncv~ = 0.989 and SEE = 0.063. The steric and electrostatic contributions were 48.8% and 51.2%, respectively. Bootstrap analysis for 100 runs was then carried out for further validation of the model by statistical sampling of the original data set to create new data sets. The higher r^2^ bootstrap value 0.992 for CoMFA with standard error value of 0.049 is supporting the statistical validity of the developed models. The predicted activities for the antagonists *versus* their experimental activities are listed in [Table 3](#t3-ijms-13-06138){ref-type="table"} and the correlation between the predicted activities and the experimental activities is depicted in [Figure 2](#f2-ijms-13-06138){ref-type="fig"}. The predictive correlation coefficient *r*^2^ ~pred~ was found to be 0.715 for the test set. Statistical results suggest that the CoMFA model is a reliable predictor.

3.2. CoMSIA
-----------

The PLS results of CoMSIA analysis using different combinations were depicted in [Table 4](#t4-ijms-13-06138){ref-type="table"}. The SEHD field descriptors exhibited highest *q*^2^, better SEE and *F* values than the others. Therefore, the combination of steric (S), electrostatic (E), hydrophobic (H) and hydrogen bond donor (D) fields was selected as the best model. The CoMSIA model gave a *q*^2^ of 0.567 with an optimized component number of 5. A high *r*^2^ ~ncv~ of 0.978 with a low SEE of 0.083 and *F* value of 241.534. High values of the electrostatic (43.0%) and hydrogen bond donor (23.6%) fields show the importance of the electrostatic and hydrogen bond donor nature of the substituents on the core. The other descriptors, steric (16.0%) and the hydrophobic (17.3%) also have contribution. The predicted activities for the antagonists *versus* their experimental activities are listed in [Table 3](#t3-ijms-13-06138){ref-type="table"} and the correlation between the predicted activities and the experimental activities is depicted in [Figure 3](#f3-ijms-13-06138){ref-type="fig"}. The predictive correlation coefficient *r*^2^ ~pred~ was found to be 0.793 for the test set. Bootstrap analysis for 100 runs was then carried out for further validation of the model by statistical sampling of the original data set to create new data set. This *r*^2^ of bootstrap value is 0.983 for CoMSIA with standard error value of 0.069, supporting further the statistical validity of the developed models. All the results indicate that the CoMSIA model is also fairly predictive.

3.3. Contour Maps Analysis
--------------------------

The best CoMFA and CoMSIA models are selected to construct the stdev\*coeff contour maps to view the field effects on the target features. All the contours represented the default 80% and 20% level contributions for favorable and unfavorable regions, respectively, except 70% and 30% level contributions in figure of hydrogen bond donor contour maps. The maps showed regions where differences in molecular fields are associated with differences in biological activity.

### 3.3.1. CoMFA Contour Maps

CoMFA steric contour maps are shown in [Figure 4](#f4-ijms-13-06138){ref-type="fig"}. The steric interaction is represented by green and yellow contours, while electrostatic interaction is denoted by red and blue contours. A large green contour was found near the substituent group of C-4 position indicating that bulky substituents were preferred in this region ([Figure 4a](#f4-ijms-13-06138){ref-type="fig"}). This may be the reason why compounds with alkyl substituents in this area, e.g., compounds 32, 33 and 40, are more potent AR antagonist activity than molecules without any substituent at this particular position, such as compounds 14, 15 ([Figure 4a](#f4-ijms-13-06138){ref-type="fig"}) and 22.

The CoMFA electrostatic contour plots for compounds are displayed in [Figure 5](#f5-ijms-13-06138){ref-type="fig"}. The blue contours indicate that electropositive substituents would increase the AR antagonist activity with protein, while red color indicates that they should be the electron rich groups \[[@b18-ijms-13-06138]\]. Since the red contours were found near the methoxyl group of compounds 29, which is an electron rich functionality, compounds 29 exhibit high AR antagonist activity ([Figure 5a](#f5-ijms-13-06138){ref-type="fig"}). A large blue contour was found near the methoxyl substituent on phenyl ring of compound 7 ([Figure 5b](#f5-ijms-13-06138){ref-type="fig"}), indicating that negatively charged groups are disfavored at this position, and that is a possible reason why compound 7 displays less potent AR antagonist activity than compound 29.

### 3.3.2. CoMSIA Contour Maps

The CoMSIA contour maps, derived using steric, electrostatic, hydrophobic and hydrogen bond donor fields, are represented in [Figures 6](#f6-ijms-13-06138){ref-type="fig"}--[9](#f9-ijms-13-06138){ref-type="fig"}. CoMSIA steric and electrostatic contours are more or less similar to those of the CoMFA. As in case of CoMFA, a large green contour was found overlapping the substituent group of C-4 position ([Figure 6a](#f6-ijms-13-06138){ref-type="fig"}), to indicate that bulky substituents were preferred in this region compared with compound 15 ([Figure 6b](#f6-ijms-13-06138){ref-type="fig"}).

[Figure 7](#f7-ijms-13-06138){ref-type="fig"} shows the CoMSIA electrostatic fields denoted by red and blue contours. Red contours represent regions where negatively charged substituents are preferred on ligands and blue contours indicate regions where electron-rich substituents are unfavorable for the activity. The methoxyl groups of compound 29 are all near the red areas ([Figure 7a](#f7-ijms-13-06138){ref-type="fig"}), the favored position for electronegative groups. While one the methoxyl groups of compounds 15 is near the blue contour, which means that this group is not favored in this region and will lead to a decrease in the AR antagonist activity ([Figure 7b](#f7-ijms-13-06138){ref-type="fig"}).

[Figure 8](#f8-ijms-13-06138){ref-type="fig"} shows the hydrophobic contour maps in which yellow and gray contours indicate the regions where hydrophobic and hydrophilic groups are favored by the model, respectively. A yellow contour overlapping the linker including aliphatic hydrocarbon structure of compound 21 group indicates that hydrophobic substituent at this position would increase the AR antagonist activity ([Figure 8a](#f8-ijms-13-06138){ref-type="fig"}). The two large gray contours near the hydroxyl groups indicate that hydrophilic groups at these positions are favorable. These results are quite similar to those of compound 29 ([Figure 8b](#f8-ijms-13-06138){ref-type="fig"}).

Hydrogen-bond donor contour maps from CoMSIA are shown in [Figure 9](#f9-ijms-13-06138){ref-type="fig"}. Here, the maps generated depict regions having scaled coefficients 70% (favored) or 30% (disfavored). The cyan contours represent the regions where hydrogen bond-donating groups increase the activity; the purple contours represent the regions where hydrogen bond-donating groups decrease the activity. As shown in [Figure 9a](#f9-ijms-13-06138){ref-type="fig"}, the cyan contours are near the H-bond donor, hydroxyl groups, of compound 21, whereas the methoxy groups of compound 29 are present near the purple contour ([Figure 9b](#f9-ijms-13-06138){ref-type="fig"}) as H-bond acceptors.

3.4. Docking Analysis
---------------------

Docking was employed to explore the binding mode between these curcumin derivatives and the AR, to examine the stability of 3D-QSAR models previously established. We selected the most potent antagonist 29 in the experiment to perform the deeper docking study and discussion below. In order to visualize secondary structure elements, the MOLCAD program was applied. [Figure 10a](#f10-ijms-13-06138){ref-type="fig"} showed the secondary structure of the receptor. The key residues and hydrogen bonds were labeled. As shown in [Figure 10a](#f10-ijms-13-06138){ref-type="fig"}, the oxygen atom of methoxy group acted as a hydrogen bond acceptor by forming two H-bonds with the --NH~2~ group of the HIS920 residue and the --NH-- group of the GLU893, respectively. The observations taken from [Figure 10](#f10-ijms-13-06138){ref-type="fig"} were in agreement with the corresponding CoMSIA hydrogen bond contour maps.

[Figure 10b](#f10-ijms-13-06138){ref-type="fig"} depicted the MOLCAD cavity depth potential surfaces structure of the binding site within the compound 29. The cavity depth color ramp ranges from blue (low depth values = outside of the pocket) to light red (high depth values = cavities deep inside the pocket) \[[@b20-ijms-13-06138]\]. The substituent group of C-4 position of compound 29 was oriented in a light red region which demonstrated that this part was anchored deep inside the pocket. The remaining parts of compound 29 are found in the cyan area which indicated that the benzene ring was anchored outside the pocket.

[Figure 10c](#f10-ijms-13-06138){ref-type="fig"} showed the MOLCAD lipophilic potential (LP) surface of the binding area, the color for LP ranges from brown (highest lipophilic area of the surface) to blue (highest hydrophilic area). The linker of molecule was oriented to a brown region, suggesting that a hydrophobic substituent may be favored; the methoxy group was oriented to the blue and white areas which indicated that a hydrophilic group would be favorable. The observations taken from [Figure 10c](#f10-ijms-13-06138){ref-type="fig"} satisfactorily matched those of the CoMSIA hydrophobic contour map.

[Figure 10d](#f10-ijms-13-06138){ref-type="fig"} displayed the MOLCAD hydrogen bonding sites of the binding surfaces, ligands can be docked to proteins by matching the patterns displayed on the surface, the red is hydrogen donors and the blue is hydrogen acceptors. As shown in [Figure 10d](#f10-ijms-13-06138){ref-type="fig"}, the methoxy groups were oriented to a red surface, which indicated that the surfaces of this site were hydrogen bond donors, and a hydrogen bond acceptor substituent would be favorable. The observations taken from this hydrogen bonding sites satisfactorily matched the corresponding CoMSIA hydrogen bond contour maps.

3.5. Summary of Structure-Activity Relationship
-----------------------------------------------

The structure-activity relationship revealed by 3D-QSAR and molecular docking studies were illustrated in [Figure 11](#f11-ijms-13-06138){ref-type="fig"}. The negatively charged substituents, H-bond acceptors at R1, R2, R3, and R4 position would increase the activity; the substitution at the C-4 position of the linker is very crucial for improved activity in this compound class. The hydrophobic substituent at the position of the linker would increase the activity. Biphenyl rings at the both two sides of curcumin derivatives are required for the cytotoxic same as those in bicalutamide, a known and clinically used AR antagonist. Here, the hydrophobic property of benzene ring plays a key role in the anti-androgenic activities.

3.6. Designs for New Molecules
------------------------------

Based on QSAR and docking results, antagonists 29, with the highest activity, was taken as a template to design new compounds. A set of 30 new compounds with high predicted activity were designed and assessed ([Table 5](#t5-ijms-13-06138){ref-type="table"}), these molecules were aligned to the database and their activities were predicted by the CoMFA and CoMSIA models previously established. The chemical structures and predicted pIC50 values of these compounds were shown in [Table 5](#t5-ijms-13-06138){ref-type="table"}, and the graph of their predicted pIC50 values *versus* the most active compound 29 was shown in [Figure 12](#f12-ijms-13-06138){ref-type="fig"}. Most of the designed molecules exhibited better predicted pIC50 values than compound 29 in CoMFA or CoMSIA models. Molecules D2, D3, D7, D9--14, D17, D19--20, D23--24, and D27--30 displayed significantly improved predicted activities than compound 29 in both the CoMFA and CoMSIA models. The results validated the structure activity relationship obtained by this study.

4. Conclusion
=============

In the present study, 3D-QSAR analyses have been applied to a set of curcumin derivatives. The models have proven to be statistically robust with higher *q*^2^ and *r*^2^. Also, as demonstrated in our study, 3D-QSAR and docking methods were employed to understand the structural features responsible for the affinity of the ligands for AR. These results provided crucial clues that were used to design novel androgen receptor antagonists with high predicted potent activity. A set of 30 novel derivatives were designed by utilizing the structure-activity relationship taken from the present study.
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Graph of the predicted pIC50 of the designed molecules *versus* compound 29.
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###### 

Structures and experimental anticancer activities (against human prostate cancer cell line LNCaP) of the curcumin derivatives.

  --------------------------------------------------- ---------- ---------- --------------------- ------------- --------------------- --------------------- -------------
  1                                                   H          OMe        OH                    H             H                     6.2                   5.208
  2                                                   H          OMe        OMe                   H             H                     6.6                   5.180
  3 [\*](#tfn1-ijms-13-06138){ref-type="table-fn"}    H          OH         OMe                   H             H                     5.3                   5.276
  4                                                   OMe        H          OMe                   H             H                     9.9                   5.004
  5                                                   OMe        OMe        OMe                   H             H                     5.8                   5.237
  6                                                   H          OMe        OMe                   OMe           H                     12.5                  4.903
  7                                                   H          OMe        OH                    H             (CH~2~)~2~COOEt       51.5                  4.288
                                                                                                                                                            
                                                                                                                                                            
                                                                                                                                                            
  **Compound**                                                   **R~1~**                         **X**         **IC~50~** **(μM)**   **pIC~50~**           
                                                                                                                                                            
  8                                                              CH~2~OH                          O             7.3                   5.137                 
  9                                                              H                                S             6.3                   5.201                 
  10[\*](#tfn1-ijms-13-06138){ref-type="table-fn"}               H                                NH            13.6                  4.866                 
                                                                                                                                                            
                                                                                                                                                            
                                                                                                                                                            
  **Compound**                                        **R~1~**   **R~2~**   **R~3~**              **R~4~**      **R~5~**              **IC~50~** **(μM)**   **pIC~50~**
                                                                                                                                                            
  11                                                  H          OMe        OH                    H             H                     3.8                   5.420
  12                                                  H          OMe        OMe                   H             H                     1.3                   5.886
  13                                                  H          OMe        OH                    H             (CH~2~)~2~COOEt       1.5                   5.824
  14                                                  H          OH         OMe                   H             H                     10.9                  4.963
  15                                                  OMe        H          OMe                   H             H                     11.8                  4.928
  16                                                  OMe        OMe        OMe                   H             H                     4.8                   5.319
  17                                                  H          OMe        OMe                   OMe           H                     2.9                   5.538
  18[\*](#tfn1-ijms-13-06138){ref-type="table-fn"}    H          OMe        OTHP                  H             (CH~2~)~2~COOEt       4.2                   5.377
  19                                                  H          OMe        OEt                   H             H                     6.5                   5.187
  20                                                             2.6        5.585                                                                           
  21                                                  H          Me         OH                    H             H                     1.8                   5.745
  22                                                  H          Me         OMe                   H             H                     7.7                   5.114
                                                                                                                                                            
                                                                                                                                                            
                                                                                                                                                            
  **Compound**                                        **R~1~**   **R~2~**   **R~3~**              **R~4~**      **R~5~**              **IC~50~** **(μM)**   **pIC~50~**
                                                                                                                                                            
  23                                                  H          OMe        OH                    H             H                     3.3                   5.481
  24                                                  H          OH         OMe                   H             H                     4.8                   5.319
  25                                                  OMe        OMe        OMe                   H             H                     7.7                   5.114
  26[\*](#tfn1-ijms-13-06138){ref-type="table-fn"}    H          OMe        OMe                   OMe           H                     8.6                   5.066
  27                                                  H          OMe        OH                    H             (CH~2~)~2~COOEt       2.1                   5.678
                                                                                                                                                            
                                                                                                                                                            
                                                                                                                                                            
  **Compound**                                        **R~1~**   **X**      **IC~50~** **(μM)**   **pIC~50~**                                               
                                                                                                                                                            
  28 [\*](#tfn1-ijms-13-06138){ref-type="table-fn"}   OH                    3.1                   5.509                                                     
  29                                                  OMe                   0.2                   6.699                                                     
  30                                                  OTHP                  2.6                   5.585                                                     
  31 [\*](#tfn1-ijms-13-06138){ref-type="table-fn"}   OMe                   2.2                   5.658                                                     
  32                                                  OMe                   0.4                   6.398                                                     
  33                                                  OMe                   0.6                   6.222                                                     
  34 [\*](#tfn1-ijms-13-06138){ref-type="table-fn"}   OMe                   0.2                   6.699                                                     
  35                                                  OH                    8.8                   5.056                                                     
  36                                                  OTHP                  7.3                   5.137                                                     
  37                                                  OH                    6.3                   5.201                                                     
  38                                                  OMe                   3.4                   5.469                                                     
  39                                                  OH                    4.4                   5.357                                                     
  40                                                  OMe                   0.2                   6.699                                                     
  --------------------------------------------------- ---------- ---------- --------------------- ------------- --------------------- --------------------- -------------

Compounds taken for the test set.

###### 

Statistical quality parameters of different molecular interaction field methods.

  Component [a](#tfn2-ijms-13-06138){ref-type="table-fn"}                                                                   *q*^2^[b](#tfn3-ijms-13-06138){ref-type="table-fn"}   *r*^2^~ncv~ [c](#tfn4-ijms-13-06138){ref-type="table-fn"}   *F*[d](#tfn5-ijms-13-06138){ref-type="table-fn"}   SEE[e](#tfn6-ijms-13-06138){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  A--CoMFA region focusing model in Gs = 1 in various numbers of components [f](#tfn7-ijms-13-06138){ref-type="table-fn"}                                                                                                                                                                        
  1                                                                                                                         0.306                                                 0.533                                                       35.367                                             0.357
  2                                                                                                                         0.396                                                 0.738                                                       42.156                                             0.272
  3                                                                                                                         0.501                                                 0.893                                                       80.916                                             0.176
  4                                                                                                                         0.590                                                 0.955                                                       149.067                                            0.116
  5                                                                                                                         0.629                                                 0.978                                                       237.429                                            0.083
  **6**                                                                                                                     **0.658**                                             **0.988**                                                   **352.278**                                        **0.063**
  B--CoMFA model in Gs = 2 in various numbers of components [f](#tfn7-ijms-13-06138){ref-type="table-fn"}                                                                                                                                                                                        
  1                                                                                                                         0.209                                                 0.395                                                       23.191                                             0.395
  2                                                                                                                         0.273                                                 0.688                                                       33.010                                             0.297
  3                                                                                                                         0.399                                                 0.881                                                       71.577                                             0.186
  4                                                                                                                         0.432                                                 0.940                                                       109.490                                            0.135
  5                                                                                                                         0.526                                                 0.976                                                       223.159                                            0.086
  6                                                                                                                         0.564                                                 0.986                                                       304.611 0.068                                      

Optimum number of components (ONC) obtained from cross-validated PLS analysis and same used in final non-cross-validated analysis;

*q*^2^: Cross-validated correlation coefficient;

*r*^2^ ~ncv~: Non-cross-validated correlation coefficient;

*F*: F-test value;

SEE: Standard error of estimate;

Column filtering = 1.0 kcal/mol.

###### 

Comparative Molecular Field Analysis (CoMFA)/Comparative Similarity Indices Analysis (CoMSIA) predicted activity (PIC50) of compounds.

  Compound                                            Predicted Activity (CoMFA)   Predicted Activity (CoMSIA)
  --------------------------------------------------- ---------------------------- -----------------------------
  1                                                   5.191                        5.124
  2                                                   5.163                        5.257
  3[\*](#tfn8-ijms-13-06138){ref-type="table-fn"}     4.963                        4.896
  4                                                   4.971                        4.935
  5                                                   5.277                        5.202
  6                                                   4.900                        4.964
  7                                                   4.323                        4.333
  8                                                   5.145                        5.144
  9                                                   5.208                        5.242
  10 [\*](#tfn8-ijms-13-06138){ref-type="table-fn"}   5.264                        5.243
  11                                                  5.463                        5.495
  12                                                  5.929                        5.925
  13                                                  5.763                        5.850
  14                                                  5.003                        4.960
  15                                                  4.929                        4.879
  16                                                  5.281                        5.325
  17                                                  5.522                        5.567
  18 [\*](#tfn8-ijms-13-06138){ref-type="table-fn"}   5.235                        5.175
  19                                                  5.167                        5.020
  20                                                  5.589                        5.586
  21                                                  5.684                        5.634
  22                                                  5.115                        5.187
  23                                                  5.526                        5.554
  24                                                  5.255                        5.249
  25                                                  5.157                        5.115
  26 [\*](#tfn8-ijms-13-06138){ref-type="table-fn"}   5.412                        5.260
  27                                                  5.642                        5.747
  28 [\*](#tfn8-ijms-13-06138){ref-type="table-fn"}   5.540                        5.389
  29                                                  6.580                        6.606
  30                                                  5.559                        5.697
  31 [\*](#tfn8-ijms-13-06138){ref-type="table-fn"}   6.039                        5.800
  32                                                  6.543                        6.543
  33                                                  6.347                        6.169
  34 [\*](#tfn8-ijms-13-06138){ref-type="table-fn"}   6.407                        6.487
  35                                                  5.013                        5.072
  36                                                  5.094                        5.062
  37                                                  5.290                        5.186
  38                                                  5.507                        5.567
  39                                                  5.337                        5.353
  40                                                  6.603                        6.529

Compounds taken for the test set.

###### 

Regression summary of CoMFA and CoMSIA models.

                                                                                                                                Field Contribution in %                                    
  ------------------------------------------------------- ------- ----------- ----------- ----------- ----------- ------------- ------------------------- ---------- ---------- ---------- ------
  CoMFA                                                                                                                                                                                    
  SE                                                      6       0.658       0.988       0.715       0.063       352.278       48.8                      51.2       --         --         --
  CoMSIA [b](#tfn10-ijms-13-06138){ref-type="table-fn"}                                                                                                                                    
  SE                                                      5       0.498       0.967                   0.102       156.626       27.2                      72.8       --         --         --
  SHE                                                     6       0.536       0.985                   0.069       292.088       19.6                      57.6       22.7       --         --
  SED                                                     6       0.519       0.983                   0.075       247.310       22.3                      52.0       --         25.7       --
  SEA                                                     5       0.404       0.965                   0.105       148.070       19.7                      55.0       --         --         25.3
  **SEHD**                                                **5**   **0.567**   **0.978**   **0.793**   **0.083**   **241.534**   **16.0**                  **43.0**   **17.3**   **23.6**   --
  SEDA                                                    5       0.486       0.969                   0.098       170.503       15.6                      38.9       --         23.5       21.9
  SEHA                                                    6       0.426       0.983                   0.074       255.498       15.3                      45.9       17.8       --         20.9
  SEHDA                                                   6       0.514       0.983                   0.074       250.217       12.7                      33.4       14.3       21.6       18.0

*r*^2^ ~pred~: Predictive *r*^2^;

Field contributions: Steric (S) and electrostatic (E) field from CoMFA; Steric (S), electrostatic (E), hydrophobic (H), donor (D), and acceptor (A) fields from CoMSIA.

###### 

The structures and predicted pIC50 values of newly designed derivatives.

  ----- ---------- ---------- ---------------------- ------- -------
  29    OMe        OMe        CH=CHCOOEt             6.582   6.599
  D1    CN         CN         CH=CHCOOEt             6.817   6.583
  D2    SO~3~H     SO~3~H     CH=CHCOOEt             6.714   6.619
  D3    NO~2~      NO~2~      CH=CHCOOEt             6.696   6.876
  D4    CF~3~      CF~3~      CH=CHCOOEt             6.651   6.544
  D5    COOH       COOH       CH=CHCOOEt             6.293   6.840
  D6    CHO        CHO        CH=CHCOOEt             6.691   6.506
  D7    Br         Br         CH=CHCOOEt             6.783   6.583
  D8                          CH=CHCOOEt             6.773   6.196
  D9    NO~2~      CN         CH=CHCOOEt             6.774   6.666
  D10   B(OH)~2~   B(OH)~2~   CH=CHCOOEt             6.664   6.571
  D11   CN         CN         CH=CH(CH~2~)~3~CH~3~   6.680   6.585
  D12   OMe        OMe                               6.648   6.727
  D13   OMe        OMe                               6.662   6.832
  D14   OMe        OMe                               6.670   6.740
  D15   OMe        OMe                               6.518   6.802
  D16   OMe        OMe                               6.526   6.864
  D17   CN         CN                                6.798   6.670
  D18   CN         CN                                6.787   6.787
  D19   NO~2~      NO~2~                             6.828   6.973
  D20   NO~2~      NO~2~                             6.813   7.094
  D21   COOH       COOH                              6.020   6.917
  D22   COOH       COOH                              6.112   7.058
  D23   CN         CN                                6.804   6.783
  D24   CN         CN                                6.749   6.842
  D25   COOH       COOH                              6.068   7.017
  D26   COOH       COOH                              6.053   7.084
  D27   NO~2~      NO~2~                             6.789   7.119
  D28   NO~2~      NO~2~                             6.765   7.172
  D29                                                6.641   6.863
  D30   Br         Br                                6.794   6.746
  ----- ---------- ---------- ---------------------- ------- -------
